Answer
Mirvaso (brimonidine tartrate) gel is contraindicated in patients receiving monoamine oxidase (MAO) inhibitors or tricyclic or tetracyclic antidepressants that affect noradrenergic transmission.
Sources for this answer
- Mirvaso 3mg/g GelGalderma (U.K.) Limited · emc · SmPC §4.3 Contraindications · Version 12Document updated
Sources checked